TG Therapeutics (TGTX) Tops Q2 EPS by 9c
Tweet
Share
E-mail
Get Alerts TGTX Hot Sheet
Join SI Premium – FREE
TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $73.47 million versus the consensus estimate of $65.89 million.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Mills (GIS) Tops Q1 EPS by 3c
- Veeva gains another top 20 biopharma client for its Vault CRM
- Baird Reiterates Outperform Rating on Circle Internet Group (CRCL)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
